RNS Number : 4031T
Shield Therapeutics PLC
24 March 2021

Shield Therapeutics plc
("Shield Therapeutics" or the "Company")

Block Listing Application

London, UK, 24 March 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), has today made an application to the London Stock Exchange for a block listing of 2,500,000 ordinary shares of 1.5 pence each in the Company ("Block Listing Shares") to be admitted to trading on the London Stock Exchange ("Admission") and to be split between the schemes listed below.

The 2,500,000 Block Listing Shares are to be issued under the following schemes:

- Shield Therapeutics Retention Share Plan
- Shield Therapeutics plc 2016 Company Share Option Plan
- The Shield Therapeutics plc 2016 Long Term Incentive Plan
- Shield Therapeutics Retention and Performance Share Plan

Admission is expected to occur on 30 March 2021.

For further information, please contact:

Shield Therapeutics plc +44 (0) 191 511 8500
Tim Watts (CEO) +44 (0) 191 511 8500
Lucy Huntington-Bailey (Company Secretary and General Counsel)

Nominated Adviser and Joint Broker
Peel Hunt LLP +44 (0) 20 7148 8900

James Steel / Christopher Golden

Joint Broker
finnCap Ltd +44 (0) 20 7220 0500
Geoff Nash / Matthew Radley/ Alice Lane

Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780
Paul McManus / Lianne Cawthorne or shield@walbrookpr.com

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru® /Accrufer® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ALSFLFVDVEISFIL